Market news
HQY's growth is driven by rising HSA assets and AI-led efficiencies, while cybersecurity risks remain a key concern.
HealthEquity (NASDAQ:HQY) posted second-quarter fiscal 2027 results on August 27, which pushed revenue growth to 8% year over year, up from the 7% pace set over the first half of the year, a rare acceleration for a company already sitting on 10.7 million health savings accounts/HSAs. Adjusted EBITDA jumped 11% to $167 million, translating into […]
Detailed price information for Healthequity (HQY-Q) from The Globe and Mail including charting and trades.
HealthEquity (HQY) has an average rating of Buy and mean price target of $114.63, according to analy
After comparing the best health savings account (HSA) providers’ investment options, fees, and customer experiences, we found Fidelity to be the top choice.
Sales and earnings beats in fiscal Q2 weren't enough to satisfy investors.
Detailed price information for Humana Inc (HUM-N) from The Globe and Mail including charting and trades.
Tipranks Press Release.
Detailed price information for Healthequity (HQY-Q) from The Globe and Mail including charting and trades.
HealthEquity (HQY) is back in focus after reporting second quarter results on 27 August 2026, along with higher full year guidance, a completed share repurchase tranche and a new employee stock plan related shelf registration. Despite the strong Q2 update and raised full year guidance, HealthEquity’s share price has pulled back sharply in the very short term, with a 1 day share price return of down 10.6% and a 7 day return of down 10.4%. That sits against a 90 day share price return of 6.1%...
HealthEquity (HQY) delivered better-than-expected Q2 results, keeping its margin runway and fiscal 2
Moby summary of HealthEquity, Inc.'s Q2 2027 earnings call
HealthEquity (NASDAQ:HQY) reported accelerated revenue growth and record profitability in its fiscal 2027 second quarter, citing HSA account expansion, higher member engagement and technology-driven service efficiencies. The company raised its full-year outlook after generating record adjusted EBITD
HealthEquity’s second-quarter results combined higher revenue and earnings with record HSA accounts, assets and Adjusted EBITDA margin, prompting management to increase its full-year outlook. Key Investor TakeawaysHealthEquity (NASDAQ:HQY) raised fiscal 2027 guidance after second-quarter revenue increased 8% year over year to $350.
While the top- and bottom-line numbers for HealthEquity (HQY) give a sense of how the business performed in the quarter ended July 2026, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.
HealthEquity (HQY) delivered earnings and revenue surprises of +4.20% and +0.14%, respectively, for the quarter ended July 2026. Do the numbers hold clues to what lies ahead for the stock?
HealthEquity: Fiscal Q2 Earnings Snapshot
Motley Fool Press Release.
Highlights of the second quarter include:
HealthEquity Inc (HQY) delivers record Q2 results with 8% revenue growth and a 48% adjusted EBITDA margin, fueled by AI-driven efficiencies and strong HSA member engagement.
(Updates with share price movement in the headline and first paragraph.) HealthEquity (HQY) share
Adrian T Dillon, Director, on August 25, 2026, sold 7,632 shares in Healthequity (HQY) for $798,373.
Beyond analysts' top-and-bottom-line estimates for HealthEquity (HQY), evaluate projections for some of its key metrics to gain a better insight into how the business might have performed for the quarter ended July 2026.
DRAPER, Utah, Aug. 03, 2026 (GLOBE NEWSWIRE) -- HealthEquity, Inc. (NASDAQ: HQY) (“HealthEquity” or the “Company”), the largest independent health savings account (HSA) custodian by account volume and a leader in consumer-directed benefits (CDB), today announced plans to release financial results for its second quarter of fiscal 2027, before the opening of regular stock market trading on Thursday, August 27, 2026. Following the news release, HealthEquity management will host a conference call fo
HealthEquity (HQY) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
Detailed price information for Healthequity (HQY-Q) from The Globe and Mail including charting and trades.
HQY benefits from strong HSA growth, AI-driven automation and solid first-quarter fiscal 2027 results despite data security risks.
This is the newest page. Registered accounts read further back.